Lyra Therapeutics Inc (NAS:LYRA)
$ 0.1806 0.0083 (4.82%) Market Cap: 11.28 Mil Enterprise Value: -5.02 Mil PE Ratio: 0 PB Ratio: 0.55 GF Score: 39/100

Lyra Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript

May 13, 2021 / 08:15PM GMT
Release Date Price: $7.46 (-6.28%)
Jason Gerberry
Bank of America - Analyst

Good day, everybody. Thank you for joining us at the Bank of America annual healthcare conference being conducted virtually this year. My name is Jason Gerberry. I'm one of the biopharma analysts at BofA. And I'm pleased to be introducing our next company presenter, Lyra Therapeutics; and CEO, Maria Palasis, who has some slides that she's going to run through. So I'm going to hand the mic over to Maria. So Maria, it's all yours.

Maria Palasis
Lyra Therapeutics - President and CEO

Great, thank you, Jason. It's great to be here. Thank you for the invitation. And I am going to start on slide number 3, investment summary.

So we, now, at Lyra Therapeutics have completed three clinical studies on LYR-210. Both of the products that are in development right now are targeting Chronic Rhinosinusitis. In the US, there is 14 million patients that have CRS, and globally, it's a large problem throughout the world.

In the US, there are no FDA approved medicines to treat the indication of CRS. And in fact, the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot